Contact
searchSearch
HMP Global

Meeting Materials

Poster

1
(#1) Clinician Perspectives on the Efficacy and Safety/Tolerability of Olanzapine Compared With Other Antipsychotics: Results From the SONAR (Survey on Olanzapine Needs and Attitudes Research) Study
Abstract: Olanzapine is a second-generation antipsychotic with a well-established efficacy:safety profile. Since olanzapineís approval in 1996 for treatment of schizophrenia, more antipsy...
07/10/2025
10
(#10) Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From an Additional Randomized, Double-Blind, Phase 3 Trial
Abstract: Background: Lumateperone is FDA-approved to treat schizophrenia and bipolar depression. This Phase 3, randomized, double-blind, placebo-controlled, multicenter trial (NCT0506170...
07/10/2025
11
(#11) Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress
Abstract: Background: Lumateperone is FDA-approved to treat schizophrenia and depressive episodes associated with bipolar I or II disorder.
07/10/2025
12
(#12) Change in Clinician-Rated and Patient-Reported Depression Severity After Esketamine Nasal Spray as Monotherapy in Adult Patients With Treatment-Resistant Depression: A Post Hoc Analysis of Item Scores
Abstract: Objective: To evaluate improvements in items of the Montgomery-≈sberg Depression Rating Scale (MADRS) and Patient Health Questionnaire-9 (PHQ-9) over 4 weeks of esketamine nasal...
07/10/2025
13
(#13) CT-152, a Prescription Digital Therapeutic for Major Depressive Disorder: A Real-World Analysis of Durability of Treatment Effect
Abstract: Introduction: CT-152 is a prescription digital therapeutic for treating patients with major depressive disorder (MDD) as an adjunct to antidepressant medication. The durability ...
07/10/2025
14
(#14) Efficacy of CT-152 for Major Depressive Disorder Using the Self-Reported 9-Item Patient Health Questionnaire in Participants With Baseline Anxiety Symptoms and/or Difficulty Sleeping
Abstract: Introduction: CT-152 is a prescription digital therapeutic adjunct to antidepressant medication for patients with major depressive disorder (MDD) that has shown benefit over sha...
07/10/2025
15
(#15) Responders and Participant-Reported Depressive Symptom Clusters That may Benefit From CT-152 Therapy for Major Depressive Disorder
Abstract: Introduction: CT-152 is a prescription digital therapeutic adjunct to antidepressant medication for patients with major depressive disorder (MDD). In the Mirai trial (NCT0477028...
07/10/2025
16
(#16) Symptoms of Major Depressive Disorder That Potentially Benefit From the Digital Therapeutic CT-152
Abstract: Introduction: CT-152 is a prescription digital therapeutic adjunct to antidepressant medication for patients with major depressive disorder (MDD). This post hoc analysis of the ...
07/10/2025
17
(#17) Early Dose Management and Up-Titration of Esketamine to 84 mg in the Double-Blind Induction Phase of the Randomized, Active-Controlled, Phase 3 TRANSFORM-2 Study
Abstract: Background: The Phase 3 TRANSFORM-2 study (NCT02418585/Popova et al.Am J Psychiatry.2019;176[6]:428-438) evaluated the efficacy and safety of esketamine nasal spray and supporte...
07/10/2025
18
(#18) Efficacy and Safety of a Single Administration of the N-methyl-D-aspartate Subunit 2B-Selective Negative Allosteric Modulator, BI 1569912, in People Living with Major Depressive Disorder: A Phase Ib Randomized Controlled Trial
Abstract: Background: BI 1569912 is a selective negative allosteric modulator of NR2B subunit-containing NMDA receptors (NR2B NAM) in development for major depressive disorder (MDD). Me...
07/10/2025
19
(#19) Efficacy and Safety of Esketamine Nasal Spray as Monotherapy in Adult Patients with Treatment-Resistant Depression for up to 4-Months of Treatment: A Post Hoc Analysis
Abstract: Objective: To evaluate the efficacy and safety of esketamine nasal spray (ESK) monotherapy in adults with treatment-resistant depression (TRD) from a multicenter study (NCT04599...
07/10/2025
2
(#2) d-Amphetamine Transdermal System in Treatment of Children and Adolescents With ADHD: ADHD-RS-IV Score Analysis From a Pivotal Trial
Abstract: Background: In a pivotal study, the dextroamphetamine transdermal system (d-ATS) met primary and secondary efficacy endpoints for ADHD in children and adolescents. d-ATS efficac...
07/10/2025
20
(#20) Empowering Patients as Educators: Transforming Patient Questions and Insights into Enhanced Clinical Knowledge and Practice
Abstract: Goal: This project investigates how patients undergoing active treatment with a novel FDA-approved antidepressant, esketamine for treatment-resistant depression, can meaningfull...
07/10/2025
21
(#21) Esketamine Following Failure of Transcranial Magnetic Stimulation in Patients with Treatment Resistant Depression
Abstract: Major depressive disorder is the leading cause of disability worldwide. Almost a third of patients with major depression failed to achieve remission despite treatment with multi...
07/10/2025
22
(#22) Initiating dextromethorphan 45 mg-bupropion 105 mg (AXS-05) in Patients with Major Depressive Disorder (MDD): Expert Panel Consensus Recommendations
Abstract: Background: In the treatment of MDD, critical needs remain for improved patient outcomes through medications with novel mechanisms of action (MOA). Dextromethorphan 45 mg-buprop...
07/10/2025
24
(#24) Long-Term Safety and Efficacy of Esketamine Nasal Spray as Monotherapy: A Post Hoc Analysis of the SUSTAIN-3 Study
Abstract: Introduction: Esketamine nasal spray (ESK) is approved for treatment of adults with treatment-resistant depression as monotherapy or with an oral antidepressant (OAD). SUSTAIN-3...
07/10/2025
25
(#25) Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial
Abstract: Background: Lumateperone is FDA-approved to treat schizophrenia and bipolar depression. This Phase 3, randomized, double-blind, placebo-controlled, multicenter trial (NCT0498594...
07/10/2025
26
(#26) Real-World Experience with Treatment and Expectations by Satisfaction Status of Persons with Major Depressive Disorder
Abstract: People treated for Major Depressive Disorder (MDD) exhibit varying levels of satisfaction and differing expectations regarding their MDD treatments. This study examines the rela...
07/10/2025
27
(#27) A Rare Case of Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT) Presenting with Stroke-like Symptoms
Abstract: Lithium is a lifesaving medication and the gold standard for management of bipolar disorder. It has a narrow therapeutic index, making toxicity an important clinical concern. Th...
07/10/2025
28
(#28) A Qualitative, Interview-based Study of Patient, Caregiver, And Prescriber Rankings of Functional Outcome Improvements in Schizophrenia
Abstract: Functional impairment in schizophrenia results in substantial burden to patients, caregivers, and healthcare systems. Addressing this impairment remains a critical unmet need in...
07/10/2025
29
(#29) Advancing Schizophrenia Treatment: A Modified Delphi Consensus on The Critical Role of Psychiatric Pharmacists in Prescription Digital Therapeutics
Abstract: Background: Prescription digital therapeutics (PDTs) are software-based interventions for managing and treating medical conditions prescribed by healthcare providers and dispens...
07/10/2025
3
(#3) Effect of Centanafadine on the AIM-A After 6 Weeks of Treatment in Adults with ADHD: A Pooled Analysis of Two Phase 3 Trials
Abstract: Objective: ADHD is a chronic and prevalent neurodevelopmental disorder in adults, characterized by symptoms of inattention, hyperactivity, and impulsivity. This pooled analysis ...
07/10/2025
30
(#30) Association of Antipsychotic Medication Nonadherence With All-Cause Mortality in Newly Treated Adults With Schizophrenia: A Retrospective Healthcare Claims Study
Abstract: Background: Clinical data support an association between antipsychotic nonadherence and adverse outcomes in schizophrenia; however, the influence of nonadherence on mortality re...
07/10/2025
31
(#31) Baseline Severity of Illness and Response to Treatment With Aripiprazole Lauroxil Every 2 Months: A Post Hoc Analysis of Phase 3 ALPINE Clinical Trial Data
Abstract: OBJECTIVE: This post hoc analysis examined the efficacy and safety of aripiprazole lauroxil (AL) every-2-months for the treatment of schizophrenia by baseline severity of illnes...
07/10/2025
32
(#32) Clozapine Toxicity in Real-World Practice: The Critical Role of Rapid Therapeutic Drug Monitoring
Abstract: Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, but it requires careful monitoring due to its narrow therapeutic index and potential for lif...
07/10/2025
33
(#33) Earlier Use of Long-Acting Injectable Paliperidone Palmitate versus Oral Antipsychotics in Patients With Schizophrenia: A Post-hoc Analysis From PROSIPAL
Abstract: Objective: The analysis evaluated outcomes following initiation of paliperidone palmitate 1-month (PP1M) vs oral antipsychotics (OAPs) within ?3-years and >3-5-years of a sch...
07/10/2025
34
(#34) Efficacy of Olanzapine Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use Demonstrated in Patients With Schizophrenia: Results From a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial (SOLARIS)
Abstract: TV-44749 is a once-monthly, subcutaneous, extended-release injectable based on innovative copolymer delivery technology that ensures controlled release of olanzapine, designed t...
07/10/2025
35
(#35) Enabling Conversations About Long-Acting Injectable Antipsychotics Among HCPs, Patients, and Caregivers With the Long-Acting Injectables: Conversations and Resources for Education (LAI-CARE) Website
Abstract: Background: For people with schizophrenia, long-acting injectable antipsychotics (LAIs) can improve adherence and clinical outcomes versus oral antipsychotics, yet remain underu...
07/10/2025
36
(#36) Engagement, Effectiveness, and Patient Experience of an Investigational Digital Therapeutic for Experiential Negative Symptoms of Schizophrenia: An Exploratory Study
Abstract: Background: CT-155/BI 3972080 is an investigational digital therapeutic for treatment of experiential negative symptoms (ENS) of schizophrenia. Methods: This multicenter, 7-wee...
07/10/2025
37
(#37) Exploration of Negative Symptoms and Digital Application Use in People with Schizophrenia
Abstract: Background: Negative symptoms of schizophrenia (NS) profoundly impact functional outcomes. As there are currently no approved pharmacotherapies for NS, innovative treatments are...
07/10/2025
38
(#38) Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Bipolar I Disorder
Abstract: OBJECTIVE: Combination olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. OLZ/SAM treatme...
07/10/2025
39
(#39) Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia
Abstract: OBJECTIVE: Combination olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. OLZ/SAM treatme...
07/10/2025
4
(#4) Impact of Centanafadine on Executive Functioning in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder: Analysis of Conners 3 and Exit Survey Responses
Abstract: Objective: To compare the executive functioning (EF) efficacy measure with patient exit interviews in a pediatric population treated with centanafadine (CTN), a norepinephrine, ...
07/10/2025
40
(#40) How Same-Day Clozapine Levels can Improve Nonadherence Detection and Guide Treatment Strategies
Abstract: Antipsychotic nonadherence increases the risk of relapse, rehospitalization, and adverse outcomes for patients. Monitoring medication adherence is challenging because patient se...
07/10/2025
41
(#41) Long-acting Injectable Treatments for Schizophrenia: Differences in Attitudes and Preferences Among Healthcare Professionals and Patients From the SOLARIS Trial Experiences Study
Abstract: TV-44749 is an innovative, once-monthly, subcutaneous (SC) long-acting injectable (LAI) olanzapine. TV-44749 is designed to provide sustained efficacy without oral supplementati...
07/10/2025
42
(#42) Real-World Treatment Patterns of Patients With Schizophrenia Using Oral Olanzapine and the Associated Impact of Non-adherence on Healthcare Resource Utilization
Abstract: Non-adherence to oral antipsychotics is a barrier to optimal outcomes for patients with schizophrenia. This study aimed to identify treatment patterns and the impact of treatmen...
07/10/2025
43
(#43) Use Of Machine Learning to Identify Variations in Clinical Characteristics, Healthcare Resource Utilization, and Treatment Adherence Among Patients With Schizophrenia Initiating Oral Olanzapine Treatment
Abstract: Oral antipsychotic treatments are associated with poor adherence and high disease/healthcare resource utilization (HCRU) burden in patients with schizophrenia. Long-acting injec...
07/10/2025
44
(#44) Longitudinal Real-World Study of the Patient Journey of a National Sample of Beneficiaries with Schizophrenia Dually Eligible for Medicare & Medicaid
Abstract: Introduction: Almost half of US patients with schizophrenia are dual eligibles; however, there is limited understanding of their journey in terms of receipt of long-acting injec...
07/10/2025
45
(#45) Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use Is Designed for Sustained Efficacy and to Eliminate the Risk of Post-injection Delirium/Sedation Syndrome: In Vitro and Clinical Data
Abstract: Use of intramuscular (IM) long-acting injectable (LAI) olanzapine is limited due to a boxed warning for post-injection delirium/sedation syndrome (PDSS) and the associated Risk ...
07/10/2025
46
(#46) Perspectives of Psychiatrists and Psychiatric Nonphysicians on Treating Schizophrenia With Long-Acting Injectable Antipsychotics: Subgroup Analysis From the Multinational ADVANCE Study
Abstract: Background: Long-acting injectable antipsychotics (LAIs) improve adherence and reduce relapse compared with oral antipsychotics, but LAI use varies. This analysis of the Attitud...
07/10/2025
47
(#47) Real-World Clinical Outcomes Among Patients Receiving the Long-Acting Injectable Antipsychotic TV-46000 Versus Second-Generation Oral Antipsychotics
Abstract: Background: TV-46000 is a long-acting subcutaneous injectable form of risperidone for the treatment of schizophrenia in adults.
07/10/2025
48
(#48) Treatment Patterns and Healthcare Resource Utilization Among Patients Receiving the Long-Acting Injectable Antipsychotic TV-46000 Versus Second-Generation Oral Antipsychotics
Abstract: Background: Long-acting injectable antipsychotics (LAIs) have been associated with improved adherence and outcomes when compared with oral antipsychotics (OAs).
07/10/2025
49
(#49) Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: A Patient Subgroup Analysis of a 4-Year Open-Label Study
Abstract: Objective: To analyze subgroup data from a 4-year, open-label study of combined olanzapine and samidorphan (OLZ/SAM) in adults with schizophrenia, schizophreniform disorder, or ...
07/10/2025
5
(#5) Effect of External Heat Application on the Pharmacokinetics of d-Amphetamine Transdermal System and Comparison of Pharmacokinetics of d-Amphetamine Transdermal System With Oral Formulations
Abstract: Background: d-Amphetamine transdermal system (d-ATS) is a transdermal dextroamphetamine formulation approved for treating ADHD patients aged ?6 years. This study evaluates the e...
07/10/2025
50
(#50) Schizoaffective Disorder Complicated by Prolonged Childhood Khat Use: A Case Report
Abstract: This is a case involving a 23-year-old male patient with a history of heavy khat use in early childhood, who was diagnosed with bipolar type schizoaffective disorder at the age ...
07/10/2025
51
(#51) Social Determinants of Health among Patients with Experiential Negative Symptoms Living with Schizophrenia: Medical Expenditure Panel Survey
Abstract: Introduction: Experiential negative symptoms (ENS) of schizophrenia include avolition, asociality, and anhedonia, which impact quality of life and functioning. This study assess...
07/10/2025
52
(#52) Estimation of the Minimal Clinically Important Difference (MCID) and Longitudinal Change in the Tardive Dyskinesia Impact Scale (TDIS), a Validated, Tardive Dyskinesia-Specific, Patient-Reported Outcome Measure
Abstract: Tardive Dyskinesia Impact Scale (TDIS) evaluates TD symptom impact over the previous 7 days and was a KINECTÆ3, KINECTÆ4, and KINECT-PRO outcome. Objectives were to estimate min...
07/10/2025
53
(#53) Clinical and Demographic Characteristics of Patients Taking Antipsychotics and Treatment Patterns Among Patients With Tardive Dyskinesia in a Long-Term Care Setting
Abstract: Background: This study described the clinical/demographic characteristics of patients taking antipsychotics/metoclopramide in a long-term care (LTC) setting and treatment patter...
07/10/2025
54
(#54) Multidimensional Impact of Tardive Dyskinesia Reported by Clinicians: Second Interim Analysis From the IMPACT-TD Registry
Abstract: Background: We previously assessed the multidimensional impact of tardive dyskinesia (TD) on an initial population of individuals (n=286) in the IMPACT-TD Registry. Here, we rep...
07/10/2025
55
(#55) Multidimensional Impact of Tardive Dyskinesia: Second Interim Analysis of a Patient-Reported IMPACT Measure in the IMPACT-TD Registry
Abstract: Background: We previously assessed patient-reported multidimensional impact of tardive dyskinesia (TD) on an initial set of participants (n=286) in the IMPACT-TD Registry. Here,...
07/10/2025
56
(#56) Real-World Evidence of Patient Experience With Once-Daily Deutetrabenazine Extended-Release Tablets for the Treatment of Tardive Dyskinesia in the United States
Abstract: Background: Deutetrabenazine is approved by the Food and Drug Administration for treatment of tardive dyskinesia (TD) and chorea in Huntington disease (HD). This study aimed to ...
07/10/2025
57
(#57) Remission of Tardive Dyskinesia in Patients Receiving Long-Term Valbenazine Treatment
Abstract: Once-daily valbenazine is approved for tardive dyskinesia (TD) and chorea associated with Huntingtonís disease. In a 48-week open-label study (KINECTÆ 4 [NCT02405091]), treatmen...
07/10/2025
58
(#58) Valbenazine Improves the Impacts and Symptoms of Tardive Dyskinesia: Topline Results from the Phase 4 KINECT-PRO Study
Abstract: Once-daily valbenazine is approved for tardive dyskinesia (TD) and Huntingtonís chorea. KINECT-PRO is the first study to report the effects of an approved TD medication on the i...
07/10/2025
59
(#59) A Literature Review of SSRI-Induced Akathisia and its Potential Role in Suicidality
Abstract: Objectives: This review aims to provide an overview of SSRI-induced akathisia, examining its prevalence, underlying mechanisms, and potential role in increasing suicidality. Me...
07/10/2025
6
(#6) ADHD and Comorbid Diagnosis: Considerations of Prevalence In Clinical Settings Using Bayesian Statistics
Abstract: This presentation explores the rates of ADHD being diagnosed, suggesting potential underdiagnosis, particularly in patients presenting with anxiety and depression. These co-occu...
07/10/2025
60
(#60) Clenched Secrets: The Hidden Side Effects of Psychiatric Meds
Abstract: Bruxism, a debilitating condition characterized by involuntary teeth grinding, has been increasingly linked to pharmacological treatments, though the underlying mechanisms remai...
07/10/2025
61
(#61) The Point of No Return? Cannabis Addiction and Lasting Psychosis
Abstract: This case examines a 23-year-old male whose cannabis addiction precipitated treatment-resistant psychosis. After one year of heavy use, he developed paranoid delusions (e.g., be...
07/10/2025
63
(#63) ìThe Pregnancy Test is Lying:" A Case Report on a Four-Year Battle of Undiagnosed Delusion of Pregnancy
Abstract: Both pseudocyesis and delusion of pregnancy are so rare that most information on them is found within case reports. Considering the similar presentation and risk factors of both...
07/10/2025
64
(#64) Patient Preferences of Sodium Oxybate Treatment for Narcolepsy: RESTORE End-of-Study Survey Data
Abstract: Introduction: Immediate-release (IR) oxybates require patients to awaken 2.5 to 4 hours after their first dose for a second dose. Once-nightly sodium oxybate (ON-SXB) is an exte...
07/10/2025
65
(#65) AI Scribes in Psychiatric Mental Health: Emerging Research and the Future of Augmented Clinical Practice
Abstract: Burnout among psychiatric clinicians continues to rise due to excessive documentation, administrative demands, and limited time for direct patient care. This project explores ho...
07/10/2025
66
(#66) Mitigating Burnout in Acute Care Nurses: The Role of MBSR Program
Abstract: Burnout among nurses remains a huge problem in the healthcare setting, especially within acute care hospital settings, where long hours, high emotional demands, and complex resp...
07/10/2025
7
(#7) Connecting With The Young Patient Through Media: Children TV Shows That Portray Mental Disorders
Abstract: Background: It is essential for psychiatrists to build rapport with their patients by engaging in meaningful conversation. However, children with mental health conditions are of...
07/10/2025
8
(#8) Project C.C.R.I.S.I.S.: Community-based Crisis Response Intervention Strategies for Interdisciplinary Standardization
Abstract: nurses can be influential leaders working to improve access to care for the over 3.5 million children and adolescents in the United States who need psychiatric care but struggle...
07/10/2025
9
(#9) Efficacy and Safety of AXS-05 in Alzheimer's Disease Agitation: A Phase 3 Randomized-Withdrawal Double-Blind Placebo-Controlled Study
Abstract: Approximately 70% of individuals with Alzheimerís disease (AD) experience agitation. Current pharmacologic therapies are limited and additional treatments are needed. AXS-05 (de...
07/10/2025
68
LAI360 Learning Lab: Raising the Bar on Schizophrenia Outcomes: Optimizing the Role of Long-Acting Injectable Antipsychotics
While antipsychotic treatment is essential to achieving and maintaining remission in schizophrenia, conventional antipsychotic treatments are associated with numerous shortcomings, includ...
07/10/2025
67
Navigating the Spectrum of Bipolar Disorder: New Options with Novel Mechanisms of Action
Bipolar disorder (BD) is a serious mental illness and a notoriously challenging disease for healthcare professionals to accurately diagnose and manage. As a result, high rates of undertre...
07/10/2025
69
TD360 Learning Lab: Facing the Impact of Tardive Dyskinesia
Tardive dyskinesia (TD), which affects over 500,000 people in the United States (US), is an involuntary movement disorder associated with dopamine-receptor antagonistsñmost commonly antip...
07/10/2025

Abstracts

3427183
(#1) d-Amphetamine Transdermal System in Treatment of Children and Adolescents with ADHD: ADHD-RS-IV Score Analysis From a Pivotal Trial
Abstract: Background: In a pivotal study, the dextroamphetamine transdermal system (d-ATS) met primary and secondary efficacy endpoints for ADHD in children and adolescents. d-ATS efficac...
06/18/2026
3427186
(#10) Parent Use of Artificial Intelligence for Child Mental Health Concerns: Implications for Clinical Practice and Clinician Education
Abstract: Parents are increasingly navigating child and adolescent mental health concerns in a digital information environment. Recent literature suggests that parents frequently turn to ...
06/18/2026
3427184
(#11) Integrating Trauma-Informed Care into an Inpatient Medical Setting: A Case Report
Abstract: Key principles of a trauma-informed care (TIC) approach include promoting a sense of physical and psychological safety, emphasizing collaboration, building trust, and empowering...
06/18/2026
3427235
(#12) Clinical Profile of AXS-05 in Treating Alzheimer's Disease Agitation: Results From the ADVANCE-1 and ACCORD-1 Randomized, Placebo-Controlled Studies
Abstract: Background: Alzheimer's disease (AD) agitation is characterized by emotional distress, aggression, and disinhibition. AXS-05 (dextromethorphan-bupropion) is a novel, oral NMDA r...
06/18/2026
3427178
(#13) Effectiveness of Group Music Therapy among Geriatrics with Dementia in a Nursing Home<br /><br />to Control Agitation
Abstract: Agitation in elderly patients with dementia is a major problem thatcauses distress to families, nurses, and direct caregivers.Administering successful interventions is crucial t...
06/18/2026
3427231
(#14) Severe Hyponatremia Following Risperidone Initiation in an Elderly Woman With Chronic Kidney Disease: A Case Report
Abstract: Objective: Psychotropic-associated hyponatremia is often attributed to syndrome of inappropriate antidiuretic hormone secretion, but atypical presentations can complicate diagno...
06/18/2026
3427203
(#15) Community Violence Exposure and Pain Among Black Populations: An Integrative Review
Abstract: Background: Community violence exposure (CVE) is a significant public health issue that disproportionately affects Black communities in the United States. While its mental healt...
06/18/2026
3427222
(#16) Care Beyond Objective Vision Loss: Integrating Mental Health Support Into Clinical Practice for Vision-Threatening Disease
Abstract: Vision-threatening diseases pose a critical and growing risk to mental wellbeing. Yet, substantial gaps remain in identifying and addressing psychological distress across the st...
06/18/2026
3427232
(#17) Effect of an 8‑Week Mindfulness-Based Stress Reduction Program on Perceived Stress in Novice Nurse Practitioners
Abstract: Background: Transitioning from registered nurse (RN) to nurse practitioner (NP) is often associated with "transition shock," a period of increased perceived stress that can inte...
06/18/2026
3427191
(#18) Rapid and Sustained Remission With Esketamine Nasal Spray in Adult Patients With Treatment-Resistant Depression: Overview of Remission Rates From Six Clinical Trials
Abstract: Introduction: Attaining remission in patients with treatment-resistant depression (TRD) reduces risk for relapse, improves functioning, and reduces morbidity and mortality. Eske...
06/18/2026
3427200
(#19) Remission With Lumateperone 42 mg Adjunctive to Antidepressant Therapy in Patients With Major Depressive Disorder: Analysis of Short-Term and Long-Term Trials
Abstract: Background: Lumateperone is an atypical antipsychotic to treat schizophrenia, depressive episodes associated with bipolar I or II disorder, and major depressive disorder (MDD). ...
06/18/2026
3427187
(#2) Validity of an Online Assessment of ADHD Among a Real-World Sample of Adults Seeking Web-Based Mental Healthcare
Abstract: Objective: To compare the results of a proprietary online assessment of adult attention-deficit/hyperactivity disorder (ADHD) with the current standard of care, a clinical inter...
06/18/2026
3427219
(#20) Cognitive Impairment in Major Depressive Disorder: A Patient-Identified Priority for Functional Recovery
Abstract: Background: Cognitive impairment in major depressive disorder (MDD) affects an individual's ability to think, concentrate, and make decisions. Understanding patients' perspectiv...
06/18/2026
3427199
(#21) First Onset and Duration of Treatment-Emergent Adverse Events in Patients With Major Depressive Disorder Treated With Adjunctive Lumateperone 42 mg: A Pooled Analysis of 2 Randomized Placebo-Controlled Trials
Abstract: Background: Lumateperone is an atypical antipsychotic indicated to treat schizophrenia and bipolar depression, and as adjunctive to antidepressant therapy (ADT) for major depres...
06/18/2026
3427188
(#23) A Randomized Crossover Study Evaluating the Bioavailability of a Once-Daily Dose Lithium Carbonate Extended-Release Bi-Layer Matrix Formulation Across Regimens in Healthy Adults Under Fed Conditions
Abstract: Purpose: Bioavailability of a novel once-daily (QD) lithium carbonate extended-release (XR) 900 mg formulation was compared with two approved reference regimens: two-times-daily...
06/18/2026
3427180
(#22) Non-Clinical Risk Factors for Depression in Aphasia: Insights from the All of Us Dataset
Abstract: Background: Aphasia, a language disorder most commonly caused by neurological injury, significantly impairs daily functioning and quality of life. Depression affects over 50[AA1...
06/18/2026
3427190
(#24) Dose Proportionality of Novel Once-Daily Lithium Carbonate Extended-Release Bi-Layer Matrix Formulation at 600 and 900 Milligrams in Healthy Adults Under Fed Conditions: A Randomized Crossover Study
Abstract: Purpose: This study evaluated the dose proportionality of novel once-daily (QD) lithium carbonate extended-release (XR) bilayer matrix formulation at 600 mg and 900 mg following...
06/18/2026
3427189
(#25) Steady-State Bioequivalence of Novel Once-Daily Lithium Carbonate Extended-Release 900 Milligrams Bi-Layer Matrix Versus Twice-Daily 450 Milligrams: A Randomized Crossover Study in Fed Healthy Adults
Abstract: Purpose: This study evaluated steady-state bioequivalence of a novel once-daily (QD) lithium carbonate extended-release (XR) 900 mg formulation versus a two-times-daily (BID) li...
06/18/2026
3431343
(#26) Durability of efficacy and safety of COMP360 psilocybin for treatment-resistant depression (TRD) across 26 weeks in an ongoing double-blind, randomized, controlled phase 3 study
Abstract: Introduction: COMP360 is a proprietary synthetic psilocybin formulation under investigation for treatment-resistant depression (TRD). COMP 005 is an ongoing phase 3, randomized,...
06/18/2026
3431344
(#27) Efficacy and safety of COMP360 psilocybin for treatment-resistant depression (TRD) at primary endpoint in two ongoing phase 3 double-blind randomized controlled studies
Abstract: Introduction: COMP360 is a proprietary synthetic psilocybin formulation under investigation for treatment-resistant depression (TRD). COMP005 and COMP006 are ongoing phase 3, ra...
06/18/2026
3427198
(#28) Efficacy of Lumateperone 42 mg for the Treatment of Major Depressive Disorder: Analysis of Demographic and Clinical Subgroups in a Phase 3 Randomized Placebo-Controlled Trial
Abstract: Background: Lumateperone is an atypical antipsychotic indicated to treat schizophrenia and bipolar depression, and as adjunctive to antidepressant therapy (ADT) for major depres...
06/18/2026
3427217
(#29) Incidence of Cardiometabolic Events Among Patients With Major Depressive Disorder Treated With Antidepressants And/Or Adjunctive Antipsychotics: A Real-World Evidence Study
Abstract: Objective: Pharmacologic treatments for major depressive disorder (MDD), including antidepressants and adjunctive antipsychotics, are associated with cardiovascular and metaboli...
06/18/2026
3427195
(#3) Efficacy of Centanafadine in Children and Adolescents With ADHD and High Baseline Emotional Dysregulation: A Post Hoc Analysis of Two Phase 3 Trials
Abstract: Introduction: Two phase 3 clinical trials assessed the safety and efficacy of once-daily extended-release centanafadine, a norepinephrine, dopamine, and serotonin reuptake inhib...
06/18/2026
3427196
(#30) ProACT: A Prospective Real-World Observational Study of Adjunctive Cariprazine Treatment for Major Depressive Disorder
Abstract: Background: Most patients with major depressive disorder (MDD) do not respond to initial antidepressant monotherapy and experience residual symptoms associated with worse clinic...
06/18/2026
3427201
(#31) Effects of Dextromethorphan-Bupropion (45mg/105mg) in Participants with Major Depressive Disorder and Anxious Distress
Abstract: Background: Anxiety symptoms are common in major depressive disorder (MDD) and are associated with poor treatment response to conventional antidepressants. Dextromethorphan-bupr...
06/18/2026
3427218
(#32) Gaps in Treatment Continuity in Major Depressive Disorder: Variation by Healthcare Provider Specialty and Treatment Sequence
Abstract: Introduction: Many people with major depressive disorder (MDD) have an inadequate response to current pharmacological treatments, often resulting in frequent changes and/or disc...
06/18/2026
3427215
(#33) Real-World Utilization of Combination Treatments in MDD: A Claims-Based Analysis by Healthcare Provider Type and Place in Treatment
Abstract: Introduction: Major depressive disorder (MDD) often requires combining treatments by adding a new drug to the underlying treatment when response to initial pharmacological treat...
06/18/2026
3427216
(#34) Variation in Antidepressant Treatment Patterns across Healthcare Provider Types: A Real-World Analysis
Abstract: Introduction: Real-world management of major depressive disorder (MDD) occurs in a variety of healthcare provider (HCP) settings. Types of HCPs diagnosing MDD, and treatment seq...
06/18/2026
3427234
(#35) Characterizing Hepatic Impairment Risk Factors Among Medicare Patients with Tardive Dyskinesia
Abstract: Patients with serious mental illness (SMI) comprise most of the tardive dyskinesia (TD) population and have high rates of hepatic disease. Liver function is a clinically importa...
06/18/2026
3427245
(#36) A Complex Case of Dissociative Identity Disorder Following Early Childhood Trauma.
Abstract: Dissociative Identity Disorder (DID) is a rare and complex trauma-related psychiatric condition in which an individual develops various distinct identities that control their be...
06/18/2026
3427243
(#37) Clinical Guidance for the Use of VMAT2 Inhibitors to Treat Tardive Dyskinesia: Insights From a Multidisciplinary Panel
Abstract: Background: Tardive dyskinesia (TD) is a hyperkinetic movement disorder associated with chronic exposure to dopamine-receptor blocking agents such as antipsychotics. While vesic...
06/18/2026
3427240
(#38) Tardive Dyskinesia Educational Efforts With United States-Based Patient Advocacy Groups: An Interim Analysis of Digital Engagement With Caregivers
Abstract: Background: Individuals at risk for tardive dyskinesia (TD) and their caregivers often do not recognize TD symptoms. This study aimed to assess whether educating caregivers abou...
06/18/2026
3427236
(#39) Deutetrabenazine Long-Term Treatment Response in Adults With Tardive Dyskinesia in the RIM-TD Open-Label Extension Study: Analysis of Treatment Response Patterns
Abstract: Background: In the pivotal Phase 3 AIM-TD and ARM-TD studies, deutetrabenazine demonstrated significant improvement in tardive dyskinesia (TD), with reductions in Abnormal Invol...
06/18/2026
3427206
(#4) Executive Function Symptom Outcomes in Adults With ADHD Treated with Centanafadine: A Pooled Post hoc Analysis of Two Phase 3 Trials
Abstract: Introduction: ADHD in adults frequently includes impairments in executive functions such as organization, planning, time management, and working memory. This pooled post hoc ana...
06/18/2026
3427238
(#40) Characterization of Patients With Mild Tardive Dyskinesia Taking Deutetrabenazine in the IMPACT-TD Registry
Abstract: Background: Individuals with tardive dyskinesia (TD) with mild symptom severity were not included in clinical trials of vesicular monoamine transporter 2 (VMAT2) inhibitors. Thi...
06/18/2026
3427192
(#41) Assessment of Genetic Variants in Drug Metabolizing Enzymes Among Individuals with Treatment-Resistant Major Depressive Disorder
Abstract: Major Depressive Disorder (MDD) is a leading cause of disability in the United States and is associated with significant morbidity and mortality. Approximately 30% of MDD patien...
06/18/2026
3427210
(#42) Real-world Prescribing Patterns of Esketamine Monotherapy vs. Adjunctive Therapy in Routine Psychiatric Care
Abstract: BackgroundEsketamine (Spravato®) is an established treatment for treatment-resistant depression. Recent regulatory approval on its use without a concurrent oral antidepressant h...
06/18/2026
3427209
(#43) Response and Remission Following Esketamine Nasal Spray Initiation in Treatment-Resistant Depression: Real-World Evidence from a Multi-Site Practice
Abstract: BACKGROUND: Despite esketamine's increasing use for treatment-resistant depression (TRD), long-term evidence in routine clinical practice is limited. This study described respon...
06/18/2026
3427182
(#44) Mobile Measurement-Based Care for Symptom Monitoring in Patients Undergoing Pharmacogenomic (PGx) Testing
Abstract: Background: Patients with psychiatric illnesses face inconsistent responses to medication. Pharmacogenomic (PGx) testing can identify patients at higher risk of medication side ...
06/18/2026
3427202
(#45) Real-World Clinical Outcomes of Patients Switching to Treatment With Dextromethorphan-Bupropion (45 mg/105 mg)
Abstract: Introduction: Dextromethorphan-bupropion (45/105 mg; Auvelity®), an oral NMDA receptor antagonist and sigma-1 agonist, is approved in the US for adults with MDD. This study eval...
06/18/2026
3427242
(#46) Healthcare Provider Perspectives on Real-World Use of TV-46000, a Long-Acting Subcutaneous Formulation of Risperidone, for Bipolar I Disorder
Abstract: Background: Long-acting injectable antipsychotics (LAIs) can address adherence challenges with oral antipsychotics in bipolar I disorder (BD-I) and improve clinical outcomes. TV...
06/18/2026
3427241
(#47) Inpatient Length of Stay and Healthcare Professional Preferences for Initiating TV-46000, a Long-Acting Subcutaneous Antipsychotic, or Intramuscular Paliperidone Palmitate in Patients Hospitalized With Schizophrenia
Abstract: Background: Long-acting injectable antipsychotics (LAIs) improve adherence and reduce relapse in schizophrenia, but product-specific initiation requirements may influence hospit...
06/18/2026
3427214
(#48) Beyond Monoamines: Rethinking MDD Treatments Through AMPA Receptor Modulation
Abstract: Despite the availability of numerous pharmacologic treatments for major depressive disorder (MDD), many patients fail to achieve remission with these medications. Persistent sym...
06/18/2026
3427237
(#49) Impact of Adherence on Post-Discharge Outcomes With Long-Acting Injectable Olanzapine Pamoate or Paliperidone Palmitate After Schizophrenia Hospitalization
Abstract: Background: Olanzapine is highly efficacious for schizophrenia and has been associated with lower discontinuation than several other antipsychotics. Its long‑acting injectable (...
06/18/2026
3427208
(#5) The Neurochemical and Anxiolytic-Like Effects of Centanafadine in Preclinical Assays in the Rat and Mouse
Abstract: Introduction: Emerging clinical and nonclinical data suggest that centanafadine's pharmacological profile may extend beyond core ADHD symptoms to associated features, including ...
06/18/2026
3427213
(#50) Patients Taking Once-Daily Valbenazine Report Improved Quality of Life/Functionality and Experience Remission of Tardive Dyskinesia Symptoms With Once-Daily Valbenazine: Findings From KINECT-PRO™
Abstract: Once-daily valbenazine is approved for tardive dyskinesia (TD), a persistent movement disorder associated with physical, social, and emotional impacts. KINECT-PRO™ (NCT05859698)...
06/18/2026
3427212
(#51) Clinically Meaningful Improvements and Symptomatic Remission With Once-Daily Valbenazine in Adults With Tardive Dyskinesia
Abstract: Introduction: In KINECT® 4 (NCT02405091), a long-term open-label study of once-daily valbenazine for tardive dyskinesia (TD), participants who received 48 weeks of treatment ha...
06/18/2026
3427211
(#52) Evidence-Based Recommendations for Treating Tardive Dyskinesia With a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Abstract: Two vesicular monoamine transporter 2 (VMAT2) inhibitors, valbenazine and deutetrabenazine, are approved for the treatment of tardive dyskinesia (TD). Current treatment guidelin...
06/18/2026
3427220
(#53) Once-Daily Valbenazine Demonstrates Greater and More Predictable Exposure Than Deutetrabenazine Extended-Release: Results From a Positron Emission Tomography Study in Healthy Male Adults
Abstract: Responses from patient and clinician surveys indicate that individuals with tardive dyskinesia (TD) would benefit from a simple, predictable, and clinically effective treatment ...
06/18/2026
3427224
(#54) Inpatient Initiation of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil for the Treatment of Acute Exacerbations of Schizophrenia
Abstract: Introduction: Treatment of schizophrenia exacerbations requires balancing acute symptom control with the longer-term goal of optimizing continued outpatient treatment. Long-acti...
06/18/2026
3427225
(#55) Safety and Efficacy of Aripiprazole Lauroxil in an Outpatient Setting After Initiation During Hospitalization for an Acute Exacerbation of Schizophrenia
Abstract: Introduction: The period following discharge from an acute schizophrenia hospitalization carries a high risk of relapse, rehospitalization, suicide, and medication nonadherence....
06/18/2026
3427226
(#56) Use of an Aripiprazole Lauroxil Injection Administered Once Every Month, 6 Weeks, or 2 Months in People With Schizophrenia: A Clinician-Focused Summary of Study Data
Abstract: Introduction: Aripiprazole lauroxil (AL) is a long-acting injectable form of the antipsychotic aripiprazole designed to provide consistent plasma levels for up to 4, 6, or 8 wee...
06/18/2026
3427228
(#57) Real-World Comparison of Olanzapine/Samidorphan vs Olanzapine: Assessment of Treatment Patterns and Acute Care Events in Patients With Schizophrenia or Bipolar I Disorder
Abstract: Introduction: Combined olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. The objective o...
06/18/2026
3427229
(#58) Real-World Persistence on Olanzapine/Samidorphan Versus Other Oral Second-Generation Antipsychotics in Patients With Schizophrenia
Abstract: Introduction: Poor persistence/adherence to oral antipsychotics is common and associated with increased relapse risk. This study evaluated real-world persistence/adherence with ...
06/18/2026
3427227
(#59) Olanzapine and Samidorphan in Adults With Schizophrenia or Bipolar I Disorder: Updated Review of Clinical Data
Abstract: Introduction: Combined olanzapine and samidorphan (OLZ/SAM) received US FDA approval in 2021 for the treatment of adults with schizophrenia or bipolar I disorder (BD-I) and was ...
06/18/2026
3427207
(#6) ASRS Outcomes Across Core and Expanded Symptom Domains After 6 Weeks of Centanafadine Treatment in Adults With ADHD: A Pooled Post hoc Analysis of Two Phase 3 Trials
Abstract: Introduction: This pooled post hoc analysis of two phase 3 trials evaluated the effect of centanafadine-a norepinephrine, dopamine, serotonin reuptake inhibitor-on patient-repor...
06/18/2026
3427239
(#60) Characterization of Injection Site Reactions and Local Tolerability With Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) in Adults with Schizophrenia: Results From the Phase 3 SOLARIS Trial
Abstract: Background: Long-acting injectable antipsychotics (LAIs) have demonstrated benefits in schizophrenia; however, injection site reactions (ISRs) could contribute to treatment disc...
06/18/2026
3427194
(#61) Efficacy of Lumateperone 42 mg for the Treatment of Adults With Schizophrenia and Clinically Relevant Depressive Symptoms: Results of a Post Hoc Pooled Analysis
Abstract: Background: The efficacy and safety of lumateperone 42mg in adults with an acute exacerbation of schizophrenia were established in two 4-week, randomized, double-blind, placebo-...
06/18/2026
3427197
(#62) Long-Term Efficacy of Lumateperone 42 mg for the Treatment of Adults with Schizophrenia and Clinically Relevant Depressive Symptoms: A Post Hoc Analysis of a 1-Year Open-Label Study
Abstract: Background: Depressive symptoms are estimated to affect over half of adults with schizophrenia over their lifetime and are associated with increased rates of relapse and hospita...
06/18/2026
3427230
(#63) Safety and Effectiveness of Bupropion for Smoking Cessation During Pregnancy: A Scoping Review
Abstract: Objective: The objective of this scoping review is to understand the safety and effectiveness of Bupropion as a smoking cessation aid during pregnancy.Introduction: Smoking duri...
06/18/2026
3427179
(#64) Evaluating Buprenorphine Induction and Prescribing Practices in the ED Setting
Abstract: Despite buprenorphine's proven efficacy in treating opioid use disorder (OUD), many healthcare professionals report discomfort and unpreparedness at initiating buprenorphine wit...
06/18/2026
3427233
(#65) AI AIMS Screening Tool for Improved Early Detection of Tardive Dyskinesia
Abstract: Tardive dyskinesia (TD) is a medication-induced movement disorder associated with antipsychotic use. Although routine screening with the Abnormal Involuntary Movement Scale (AIM...
06/18/2026
3427244
(#66) Reducing stress levels in mental health patients by implementing an 8-week stress reduction program
Abstract: AbstractElevated stress worsens depression and anxiety in psychiatric populations. Screening of 71 patients across five states revealed 91.5% met criteria for depression on the ...
06/18/2026
3427223
(#67) Understanding the Optimal Timeline of Edinburgh Postnatal Depression Scale Administration During Hospital Admission
Abstract: Background: Postpartum depression (PPD) affects about one in seven people in the U.S. annually. The Edinburgh Postnatal Depression Scale (EPDS) is used to screen for PPD. PPD in...
06/18/2026
3427185
(#68) Between Freedom and Confinement: Social Control and Community Dynamics in an Open Prolonged Psychiatric Hospitalization Ward for Traumatized Women
Abstract: This qualitative study examines the dynamics of social control within an open psychiatric ward in a mental health hospital in Beer Yaacov, Israel. Although admission is voluntar...
06/18/2026
3427193
(#69) Beyond Mood And Menopause: An Identity-Informed Approach To Midlife Distress In Clinical Practice
Abstract: Midlife women frequently present to psychiatric care with anxiety, depression, insomnia, and emotional exhaustion. Although symptom-focused assessment and pharmacologic manageme...
06/18/2026
3427205
(#7) Emotional Dysregulation Symptom Outcomes in Adults With ADHD Treated with Centanafadine: A Pooled Post hoc Analysis of Two Phase 3 Trials
Abstract: Introduction: ADHD in adults frequently includes symptoms of emotional dysregulation, such as affective lability, emotional overreactivity, frustration tolerance, and anger outb...
06/18/2026
3473774
(#70) A Comparative Pharmacodynamic Framework for Dopamine 2 Receptor Engagement Across Antipsychotics
Abstract: For decades, antipsychotic efficacy has been framed around a striatal dopamine D2 receptor occupancy range of approximately 65%-80%, with higher levels linked to increased extra...
06/18/2026
3427204
(#8) Efficacy of Centanafadine in Children and Adolescents With ADHD and High Baseline Executive Dysfunction: A Post Hoc Analysis of Two Phase 3 Trials
Abstract: Introduction: Two phase 3 clinical trials assessed the safety and efficacy of once-daily extended-release centanafadine, a norepinephrine, dopamine, and serotonin reuptake inhib...
06/18/2026
3427181
(#9) Elite Athletes: The Role of Neuropsychological Testing When Providing Therapeutic Use Exemptions for "Banned" Substances
Abstract: In the World Anti-Doping Code: International Standard, Prohibited List, the World Anti-Doping Agency lists "Substances and Methods" prohibited "At All Times," and when athletes ...
06/18/2026

Psych Congress Elevate

June 3-6, 2026
Las Vegas, NV

Addressing the needs of early-career and forward-thinking mental health professionals through dynamic psychopharmacology and future-focused education combined with unique opportunities to find a mentor and network with faculty and peers.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use